Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company

Executive Summary

Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.

Advertisement

Related Content

Alexion CEO Hantson Tasked With Kicking Growth Momentum Into Gear
Alexion Hunts For A CEO While Investors Await Investigation Details
Alexion’s Son of Soliris Aims To Takes Dosing Right Down
Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval
Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel